Autogenous Vaccine for Aquaculture Market

Autogenous Vaccine for Aquaculture Market Study by Salmon, Tilapia, Bream, Labris Bergylta, Cyprinus Carpio, Sea Bass, Cyclopterus Lumpus, and Trout from 2024 to 2034

Analysis of Autogenous Vaccine for Aquaculture Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more

Autogenous Vaccine for Aquaculture Market Outlook (2024 to 2034)

The global autogenous vaccine for aquaculture market is estimated at a valuation of US$ 14.1 million in 2024 and is forecasted to increase at a 5.3% CAGR to reach US$ 23.7 million by the end of 2034.

The increasing demand for autogenous vaccines for aquaculture is attributed to their use to address some specific diseases prevalent in aquaculture farms. The requirements for efficient measures for disease prevention and control are forecast to stimulate farmers to look for ways to protect their respective aquatic species from any infection.

Rising global consumption of seafood, along with the noteworthy expansion of the aquaculture industry, is set to generate high requirements for effective disease management. Autogenous vaccines play an efficient role in mitigating the impact of disorders on aquaculture protection, therefore supporting the expansion of the autogenous vaccine for aquaculture market size.

  • Sales of autogenous vaccines for aquaculture in the United States are projected to rise at a 4.7% CAGR and reach US$ 5 million by the end of 2034.
  • Bacteria-based autogenous vaccines for aquaculture are forecast to account for 92.8% share of the global market by 2034.
  • Latin America is forecast to account for 11.5% of the global autogenous vaccine for aquaculture market share by 2034.

Autogenous vaccines can be customized as per the presence the specific pathogens on a particular farm. This customization is projected to ensure an effective and targeted response to the existing diseases, therefore making them attractive options for aquaculture farmers. Regulatory bodies are recognizing the importance of autogenous vaccines in disease management, which is further contributing to the autogenous vaccine for aquaculture market growth.

Autogenous vaccines are adopted as an effective alternative to conventional antibiotics in disease management. Increasing concerns about antibiotic resistance, along with a desire to minimize the use of antibiotics on farms in aquaculture, are projected to lead to the growing inclination of farmers toward autogenous vaccines as a sustainable solution.

Report Attributes Details
Autogenous Vaccine for Aquaculture Market Size (2024E) US$ 14.1 Million
Forecasted Market Value (2034F) US$ 23.7 Million
Global Market Growth Rate (2024 to 2034) 5.3% CAGR
Salmon Segment Market Share (2034F) 40.4%
North America Market Share (2034F) 25%
Chile Market Growth Rate (2024 to 2034) 4.5% CAGR
Key Companies Profiled
  • IDT Biologika GmbH
  • Zoetis
  • Vaccinova
  • HIPRA
  • MARINNOVAC
  • Barramundi Asia Pte Ltd.
  • Sanphar (ipeve)
  • AniCon Labor GmbH
  • Kennebec River Biosciences

Don't Need a Global Report?

save 40%! on Country & Region specific reports

What are the Prominent Autogenous Vaccine for Aquaculture Market Trends?

“Resistance to Specific Antibiotics Driving Demand for Autogenous Vaccines for Aquaculture”

A wide variety of new aquaculture vaccines have been developed over the past few years for the management of zoonotic diseases or infection profiling among some aquatic species. Therefore, R&D activities are undertaken for the management and treatment of these disorders. In subtropical or topical areas, there has been a significant increase in the requirement for aquaculture vaccines. This increased demand is attributed to the emergence of resistance to some chemotherapeutic drugs and antibiotics.

The development and commercialization of third-generation DNA vaccines against aquatic pathogens is projected to act as a developing area of R&D activities in autogenous vaccines for aquaculture. Further, these DNA vaccines are forecasted to work as incredibly effective solutions and help in the strengthening of the immune systems of respective species.

What is Denting Autogenous Vaccine for Aquaculture Market Size Expansion?

“Stringent Regulations Governing Vaccine Approval Delaying Commercialization of Vaccines”

Countries have their own regulatory processes and agencies for the approval of autogenous vaccines for aquaculture. Approval processes in various countries serve as a barrier to the commercialization of autogenous vaccines for aquaculture. In addition, the price of the distribution of autogenous vaccines for aquaculture is comparatively high, which makes service providers need to wait for a longer duration to get their profit share.

Companies are prohibited from releasing improved or new products before getting all the permits. These licensing terms are projected to lead to the slow growth of the global market.

More Insights, Lesser Cost (-50% off)

Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR

What Initiatives are New Manufacturers Taking to Secure Their Position in the Market?

“Focus on Development of Autogenous Vaccines Tailored to Specific Local Pathogens”

The focus on the development of autogenous vaccines customized according to the specific local pathogens prevalent in several regions is projected to help start-ups secure an important position. In addition, customization can help them address unique challenges encountered in aquaculture operations in different geographical locations.

Exploring innovative technologies for the development, production, and administration of vaccines is projected to help them gain a competitive edge. Advancements in biotechnology, delivery mechanisms, and molecular biology can also help enhance the effectiveness of autogenous vaccines.

Country-wise Insights

North America is forecast to account for 25% share of global market revenue by the end of 2034, as per the study published by Fact.MR. Increasing production, as well as the export of aquaculture in the region, is forecast to generate demand for effective feeds and healthcare facilities, which is projected to contribute to autogenous vaccine sales.

What Makes the United States a Prominent Market in This Business Space?

“Reduced Use of Antibiotics and Supportive Regulations for Vaccine Development”

Attribute United States
Market Value (2024E) US$ 3 Million
Growth Rate (2024 to 2034) 4.7% CAGR
Projected Value (2034F) US$ 5 Million

The United States is forecast to hold 77.6% share of the North American market by 2034.

  • According to data provided by the Chilean Salmon Council in 2021, the United States is one of the prominent exporters of salmon around the world.

There is a noteworthy increase in concerns related to antibiotic use in aquaculture, along with their impact on the environment and human health. However, autogenous vaccines offer an alternative approach to disease management, especially minimizing dependency on antibiotics.

Regulatory bodies in the United States are supporting the development of autogenous vaccines, making it comparatively easier for aquaculture producers to adopt these customized solutions. Supportive approvals and guidelines for the use of autogenous vaccines for aquaculture are projected to contribute to revenue streams in the United States.

Why are Manufacturers of Autogenous Vaccines for Aquaculture Investing in Chile?

“Increasing Production and Export of Salmon and Adoption of Advanced Production Techniques”

Attribute Chile
Market Value (2024E) US$ 72 Thousand
Growth Rate (2024 to 2034) 4.5% CAGR
Projected Value (2034F) US$ 1.12 Million

Chile is projected to account for 41% share of the Latin America market by 2034. The prominent position of Chile in the manufacturing and export of salmon is projected to lead to an inclination toward sustainability. The development of sustainable aquaculture in Chile is attributed to its competitive and comparative advantages. In addition, the growing use of salmon for human food and other purposes is contributing to the rising demand for effective healthcare facilities for them.

Prominent salmon farming businesses in the country are agreeing to control carbon and water use and minimize energy consumption. In addition, advanced production facilities have also been implemented, including online environment monitoring, underwater robotics, and many more.

Know thy Competitors

Competitive landscape highlights only certain players
Complete list available upon request

Category-wise Insights

According to the research analysis published by Fact.MR, a market research and competitive intelligence provider, fish farming companies are forecasted to account for an 81.1% share of the global market by 2034. Noteworthy expansion in aquaculture farming is projected to contribute to the profit share of fish farming companies.

Which Species Accounts for a Significant Share of Global Market Revenue?

“Increased Production of Autogenous Vaccines for Salmon”

Attribute Salmon
Segment Value (2024E) US$ 5.3 Million
Growth Rate (2024 to 2034) 6.2% CAGR
Projected Value (2034F) US$ 9.6 Million

Salmon species are forecast to hold a 40.4% share of the global market by the end of 2034. Growing demand for salmon as one of the most popular seafoods in developed countries is projected to contribute to the rising sales of autogenous vaccines. Furthermore, salmon species are comparatively preferred in aquaculture cultivation in countries such as Norway and Chile.

The steady increase in the production of aquatic creatures, particularly for human consumption, is estimated to lead to the adoption of autogenous vaccines to cure the health issues of respective species.

Which Pathogen Type is in High Demand for Vaccine Production?

“High Demand for Bacterial Conjugate Vaccines Due to Dominance of Bacteria-based Infections”

Attribute Bacteria
Segment Value (2024E) US$ 13 Million
Growth Rate (2024 to 2034) 5.4% CAGR
Projected Value (2034F) US$ 22 Million

Bacteria-based vaccines are forecast to contribute 92.8% share of the global market by 2034.

  • Aquatic Animal Health Research by the USDA (United States Department of Agriculture) determined that bacterial species from approximately 20 genera are a significant cause of illnesses in aquatic creatures.

These aquatic diseases are projected to become one of the prominent reasons for huge economic losses in the aquaculture field. Therefore, bacterial conjugate vaccines find widespread usage in aquaculture.

Competitive Landscape

Market players are focusing on strategic acquisitions to leverage innovative and new ideas. They are involved in partnerships to improve the supply chain management system. Key manufacturers are extensively focusing on addressing the requirements of sustainable aquaculture farming with the practical and effective development and manufacturing of autogenous vaccines for aquaculture.

For instance :

  • TransAlgae is projected to influence the prospects of vaccination in aquaculture with the introduction of microalgae-based technology for oral delivery in January 2021. TransAlgae and Virbas entered into a collaboration to develop a vaccine with the use of TransAlgae’s innovative technology.

Key players in the autogenous vaccine for aquaculture industry are AniCon Labor GmbH, IDT Biologika GmbH, Zoetis, Vaccinova, HIPRA, MARINNOVAC, Barramundi Asia Pte Ltd., Sanphar (ipeve), and Kennebec River Biosciences.

Segmentation of Autogenous Vaccine for Aquaculture Market Research

  • By Fish Species :

    • Salmon
    • Tilapia
    • Bream
    • Labris Bergylta
    • Cyprinus Carpio
    • Sea Bass
    • Cyclopterus Lumpus
    • Trout
  • By Pathogen Type :

    • Bacteria
    • Virus
  • By End User :

    • Fish Farming Companies
    • Aquatic Research Institutes
  • By Region :

    • North America
    • Europe
    • East Asia
    • Latin America
    • Middle East & Africa
    • South Asia & Oceania

- FAQs -

What is the valuation of the autogenous vaccine for aquaculture market?

The global autogenous vaccine for aquaculture market is estimated at US$ 14.1 million in 2024.

What is the demand valuation for autogenous vaccines for aquaculture for 2034?

Demand for autogenous vaccines for aquaculture is projected to reach a market value of US$ 23.7 million by the end of 2034.

What is the sales forecast for the global market from 2024 to 2034?

Sales of autogenous vaccines for aquaculture are forecasted to increase at 5.3% CAGR from 2024 to 2034.

What share of the market are salmon forecasted to account for by 2034?

Salmon are projected to account for 40.4% share of global market revenue by 2034.

At what rate are the sales of autogenous vaccines for aquaculture projected to increase in Chile?

The market in Chile is forecasted to rise at a CAGR of 4.5% from 2024 to 2034.

What are the benefits of autogenous vaccines?

Autogenous vaccines for aquaculture help reduce production costs, enhance immunity, contribute to public health, and offer prevention instead of cure.

- Also of Interest -

Animal Vaccines Market

Animal Vaccines Market Analysis by Product (Attenuated, Recombinant, DNA, Inactivated, Subunit Animal Vaccines), by Animal Type (Livestock, Companion Animal Vaccines), by Route of Administration (Subcutaneous, Intranasal, Intramuscular) & Regional Forecast 2022-2032

Vaccine Management Solution Market

Vaccine Management Solution Market By Component (Solutions, Services), By Model (Platform, One-point), By Subscription (New, Renew), By End Use (Public, Private) & By Region - Global Market Insights 2022-2032

Aquaculture Feed and Pharmaceutical Market

Aquaculture Feed and Pharmaceutical Market Analysis by Pharmaceuticals & Biologics and Medicated Feed for Molluscs, Shrimp, Salmon, Carp, Tilapia, and Catfish from 2024 to 2034

Autogenous Vaccine for Aquaculture Market

Schedule a Call